Lynx1 Capital Management LP
CIK 1910456 · View on SEC EDGAR ↗
- Portfolio value
- $865.5M
- Positions
- 27
- As of
- June 30, 2026
Portfolio value QoQ: +36.8% 13F does not disclose cash
- Top 10 holdings weight
- 98.82%
- Top 25 holdings weight
- 99.99%
- Positions above 1%
- 6
- Effective number of positions
- 4.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 11.22% Est. buys $102,601,678 · sells $84,029,041
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 58.7% still held
- New positions
- 6
- Increased
- 6
- Decreased
- 7
- Closed
- 2
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +88.2% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 99.8% · Options excluded: 0.0%
Sector breakdown
Full portfolio 27 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| GHRS GH Research PLC - Ordinary Shares | $356,517,181 | 41.19% | 13,263,288 | $205,185,352 | Up ×6 | ||
| CGEM Cullinan Therapeutics, Inc. - Common Stock | $163,225,335 | 18.86% | 8,963,500 | $35,854,000 | |||
| STOK Stoke Therapeutics, Inc. - Common Stock | $132,136,579 | 15.27% | 4,038,404 | $-22,968,614 | Down ×2 | ||
| AGIO Agios Pharmaceuticals, Inc. - Common Stock | $126,505,652 | 14.62% | 3,408,937 | $38,156,307 | Up ×2 | ||
| CCCC C4 Therapeutics, Inc. - Common Stock | $34,215,647 | 3.95% | 7,326,691 | $15,808,535 | Up ×1 | ||
| KRRO Korro Bio, Inc. - Common Stock | $20,274,741 | 2.34% | 1,538,296 | $2,861,230 | |||
| TCRX TScan Therapeutics, Inc. - Common Stock | $7,859,567 | 0.91% | 8,019,148 | $-239,772 | |||
| DTIL Precision BioSciences, Inc. - Common Stock | $7,470,663 | 0.86% | 950,466 | $2,052,541 | Down ×3 | ||
| NEUP Neuphoria Therapeutics Inc. - Common Stock | $3,825,183 | 0.44% | 875,328 | $262,598 | |||
| PASG Passage Bio, Inc. - Common Stock | $3,287,942 | 0.38% | 673,759 | $-1,608,134 | Up ×1 | ||
| CGON CG Oncology, Inc. - Common stock | $2,230,331 | 0.26% | 31,391 | $92,252 | Down ×1 | ||
| PLRX Pliant Therapeutics, Inc. - Common Stock | $2,049,800 | 0.24% | 1,798,070 | Up ×1 | |||
| TRDA Entrada Therapeutics, Inc. - Common Stock | $1,314,540 | 0.15% | 178,606 | $-1,356,975 | Down ×1 | ||
| VYNE VYNE Therapeutics Inc. - Common Stock | $1,059,795 | 0.12% | 1,628,700 | $86,647 | |||
| PRQR ProQR Therapeutics N.V. - Ordinary Shares | $969,828 | 0.11% | 521,413 | $858,881 | Up ×1 | ||
| TRAW Traws Pharma, Inc. - Common Stock | $471,801 | 0.05% | 559,470 | $444,208 | Up ×1 | ||
| FHTX Foghorn Therapeutics Inc. - Common Stock | $300,549 | 0.03% | 61,588 | Up ×1 | |||
| DNLI Denali Therapeutics Inc. - Common Stock | $299,844 | 0.03% | 11,658 | $-35,801,974 | Down ×1 | ||
| XNCR Xencor, Inc. - Common Stock | $292,923 | 0.03% | 18,194 | $-6,176,037 | Down ×2 | ||
| ABSI Absci Corporation - Common Stock | $246,230 | 0.03% | 21,245 | $182,495 | |||
| HOWL Werewolf Therapeutics, Inc. - Common Stock | $236,737 | 0.03% | 657,786 | $-310,936 | |||
| IMTX Immatics N.V. - Ordinary Shares | $235,381 | 0.03% | 23,236 | $-1,899,633 | Down ×2 | ||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $186,648 | 0.02% | 10,100 | Up ×1 | |||
| BOLT Bolt Biotherapeutics, Inc. - Common Stock | $118,580 | 0.01% | 30,800 | $-5,852 | |||
| NUVB Nuvation Bio Inc. Class A Common Stock | $91,045 | 0.01% | 16,029 | Up ×1 | |||
| EPRX Eupraxia Pharmaceuticals Inc. - Common Stock | $66,100 | 0.01% | 10,000 | Up ×1 | |||
| IKT Inhibikase Therapeutics, Inc. - Common Stock | $40,600 | 0.00% | 20,000 | Up ×1 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| GHRS | $356,517,181 | 41.19% | up ×6 |
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| GHRS | Bought more | +2.5M | +$205.2M |
| AGIO | Bought more | +797K | +$38.2M |
| CGEM | Price move only | +0 | +$35.9M |
| STOK | Trimmed | -725K | -$23.0M |
| CCCC | Bought more | +328K | +$15.8M |
| KRRO | Price move only | +0 | +$2.9M |
| DTIL | Trimmed | -35K | +$2.1M |
| PASG | Bought more | +50K | -$1.6M |
| TRDA | Trimmed | -33K | -$1.4M |
| HOWL | Price move only | +0 | -$311K |
5 positions hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| MRUS | Dec. 31, 2025 | 1,534,141 | $144,439,375 | No longer tracked |
| PTGX | Dec. 31, 2025 | 700,014 | $46,501,930 | 73.9% |
| KROS | March 31, 2025 | 544,001 | $8,611,536 | 7.3% |
| ADCT | Dec. 31, 2025 | 1,325,848 | $5,303,392 | -72.2% |
| ALLK | March 31, 2025 | 3,628,144 | $4,390,054 | No longer tracked |
| UPB | Sept. 30, 2025 | 219,247 | $2,407,332 | -63.0% |
| DSGN | June 30, 2026 | 119,516 | $1,271,650 | 5.9% |
| CRBU | March 31, 2025 | 680,189 | $1,081,501 | 78.5% |
| IBIO | Dec. 31, 2025 | 1,055,897 | $874,072 | -22.8% |
| ARWR | March 31, 2026 | 12,043 | $799,535 | 40.7% |
| VORXXXX | March 31, 2025 | 637,218 | $707,312 | No longer tracked |
| ALLO | Dec. 31, 2025 | 546,119 | $677,188 | 54.4% |
| NEUP | Sept. 30, 2025 | 45,806 | $325,223 | -66.5% |
| CNTA | March 31, 2025 | 17,400 | $291,450 | No longer tracked |
| MPLT | March 31, 2026 | 13,477 | $236,724 | -44.9% |
| ASMB | Sept. 30, 2025 | 10,366 | $187,832 | 34.5% |
| GBIO | March 31, 2026 | 25,000 | $142,000 | No longer tracked |
| IBIO | June 30, 2026 | 68,076 | $129,344 | -14.9% |
| RPTX | March 31, 2025 | 79,176 | $103,721 | No longer tracked |
| APLT | March 31, 2026 | 410,500 | $41,050 | No longer tracked |